, , , ,

AbbVie’s cancer drug fails to meet main goal in late-stage study

AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
, , , ,

Insomnia treatment may help ease depression during menopause

(Reuters Health) - Women going through menopause may have fewer symptoms of depression when they get treatment for insomnia than when they don't, a recent experiment suggests.
, , , ,

Samsung Bioepis biosimilar to Roche’s Herceptin wins FDA nod

The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.
, , , ,

For heart failure patients in hospital, flu boosts risk of complications, death

(Reuters Health) - When people with heart failure are hospitalized, having influenza is tied to greater odds of respiratory and kidney complications and a higher chance they won't survive to be discharged, a U.S. study suggests.
, , , ,

Lilly cancer drug fails key trial, will no longer be prescribed

Eli Lilly and Co said on Friday that its cancer treatment Lartruvo, which had won conditional approval, failed to improve patient survival in a long-term confirmatory study and will no longer be prescribed, driving the drugmaker's shares down nearly 3 percent.
, , , ,

Study links opioid epidemic to painkiller marketing

(Reuters Health) - Researchers are reporting a link between doctor-targeted marketing of opioid products and the increase in U.S. deaths from overdoses.
, , , ,

Lilly’s cancer therapy Lartruvo fails study, shares drop

Eli Lilly and Co said on Friday its cancer treatment Lartruvo, approved on an accelerated basis in 2016, failed to improve patient survival in a long-term study and will no longer be prescribed, driving shares down nearly 3 percent.
, , , ,

Immunomedics’ cancer treatment fails to win accelerated approval from the FDA

Immunomedics Inc said on Thursday the U.S. Food and Drug Administration declined to grant accelerated approval for its breast cancer treatment, sacituzumab.
, , , ,

FDA advisory panel split over Sanofi-Lexicon diabetes drug

An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.
, , , ,

Junk food ads disproportionately target black and Hispanic kids: report

(Reuters Health) - Television advertising in the U.S. for candy, fast food, sugary drinks and other unhealthy treats continues to target mostly black and Hispanic youth, according to a new report that suggests this contributes to health disparities.